Month: May 2020

Global Phase 1/2 clinical trial for BNT162 vaccine program to prevent COVID-19 infection in dose escalation phase in Europe and the U.S.; first cohorts dosed in both regionsBNT122 Phase 1/2 trial update expected at AACR Virtual Annual Meeting II in JuneEnded 1Q 2020 with cash equivalents of $495 million (€452 million) with additional $236 million (€217 million) in equity investments and non-dilutive upfront payments due in 2Q 2020 from Pfizer and Fosun PharmaConference call and webcast scheduled for May 12, 2020 at 08:00 a.m. ET (2:00 p.m. CEST)MAINZ, Germany, May 12, 2020 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and infectious diseases, today provided an update on its corporate progress...

Globale Phase-1/2-Studie für BNT162-Impfstoffprogramm zur Prävention einer COVID-19-Infektion befindet sich in der Dosiseskalationsphase in Europa und den Vereinigten Staaten; in beiden Regionen wurde jeweils die erste Kohorte behandeltUpdate zur BNT122 Phase-1/2-Studie wird im Rahmen des AACR Annual Virtual Meeting II im Juni erwartetZum Ende des ersten Quartals 2020 verfügte das Unternehmen über liquide Mittel in Höhe von 452 Millionen Euro (495 Millionen US-Dollar), mit zusätzlichen 217 Millionen Euro (236 Millionen US-Dollar) an Kapitalbeteiligungen und Vorauszahlungen ohne kapitalverwässernden Effekt von Pfizer und Fosun Pharma im zweiten QuartalTelefonkonferenz und Webcast heute um 14 Uhr MEZ (8 Uhr U.S. Eastern Time)MAINZ, Deutschland, May 12, 2020 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“),...

Revenues Q1 of $613 millionGross margin Q1 of 24.0%; adjusted gross margin 24.5%Operating margin Q1 of 7.7%; adjusted operating margin 8.3%EPS Q1 of $0.19; adjusted EPS Q1 of $0.21Free Cash for the trailing 12 months of $107 millionGuidance Q2 for revenues of $540 to $580 million and gross margins of 21.0% plus/minus 90 basis points at Q1 exchange ratesInventory reduction at distribution of $63 million in Q1MALVERN, Pa., May 12, 2020 (GLOBE NEWSWIRE) — Vishay Intertechnology, Inc. (NYSE: VSH), one of the world’s largest manufacturers of discrete semiconductors and passive components, today announced its results for the fiscal quarter ended April 4, 2020.Revenues for the fiscal quarter ended April 4, 2020 were $612.8 million, compared to $609.6 million for the fiscal quarter ended December 31, 2019, and $745.2 million for the...

LONDON, May 12, 2020 (GLOBE NEWSWIRE) — Horizonte Minerals Plc, (AIM: HZM, TSX: HZM) (‘Horizonte’ or the ‘Company’), the nickel development company focused in Brazil, announces it has today published its unaudited financial results for the three month period to 31 March 2020 and the Management Discussion and Analysis for the same period. Both of the above have been posted on the Company’s website www.horizonteminerals.com and are also available on SEDAR at www.sedar.com.Highlights for the quarterHorizonte finished the quarter with a strong cash position of £17.0m, being well funded to advance Araguaia towards being construction ready;Focused on the safety of all Group, employees and stakeholders by implementing strict health and safety policies specifically tailored to Covid-19;Both in Brazil and the UK, the teams have adapted...

Four Potential Vaccines in Development to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on the Company’s Horsepox Virus Vaccine PlatformPotential Vaccine, TNX-801, in Development to Protect Against Smallpox and Monkeypox Based on Horsepox VirusAchieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for the Management of Fibromyalgia; Topline Results Expected First Quarter 2021NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended March 31, 2020, and provided an overview of recent operational highlights.“We have continued to expand our portfolio, recently adding three new potential vaccines to protect...

– Announced Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039 – – Signed Clinical Collaboration with Allogene to Evaluate Nirogacestat in Combination with Allogeneic BCMA CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma –– Initiated a Phase 1 Clinical Trial of BGB-3245, a Selective RAF Dimer Inhibitor, in Biomarker Defined Solid Tumors Patients –STAMFORD, Conn., May 12, 2020 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today provided an update on recent company developments and reported first quarter financial results for the period ended...